Law firm investigates Alnylam after $200M revenue cut and 28% stock drop

Bragar Eagel & Squire, P.C. is investigating Alnylam Pharmaceuticals following the company's announcement of a $200 million reduction in its full-year 2026 TTR product sales guidance. This adjustment reflects slower growth after initial demand was met, causing Alnylam's stock to plunge 28.35% on July 30, 2026. The law firm is reaching out to stockholders who suffered losses to discuss potential legal claims regarding possible violations of securities laws. Investors affected are encouraged to contact the firm for more information and legal options.